Allogene Therapeutics, Inc.

Developing off-the-shelf CAR T-cell therapies for cancer and autoimmune diseases.

ALLO | US

Overview

Corporate Details

ISIN(s):: US0197701065
LEI:
Country:: United States of America
Address:: 210 EAST GRAND AVENUE, 94080 SOUTH SAN FRANCISCO
Website:: https://allogene.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies. The company's 'off-the-shelf' product platform utilizes T-cells from healthy donors to create readily available treatments designed to be more accessible, scalable, and reliable than patient-specific autologous therapies. Its clinical pipeline targets hematologic malignancies (blood cancers), solid tumors, and autoimmune diseases. Key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma (LBCL), ALLO-316 for renal cell carcinoma (ccRCC), and ALLO-329 for autoimmune diseases. Allogene leverages multiplex gene-engineering and gene-editing capabilities to develop its product candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Allogene Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Allogene Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Allogene Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
HLB INC. A diversified group in pharma, shipbuilding, life sciences, and professional advisory services.	South Korea	028300
HLB Life Science CO.,LTD. Develops anti-cancer drugs and distributes IVD medical devices and lab supplies internationally.	South Korea	067630
HLB PANAGENE Co., LTD. A global leader in PNA technology for cancer diagnostics and precision medicine.	South Korea	046210
HLB Pep Co., Ltd. Develops and produces GMP peptides, APIs, and custom synthesis for the biopharma industry.	South Korea	196300
HLB PHARMACEUTICAL CO., LTD. Researches cancer drugs and offers pharmaceutical CMO and manufacturing services.	South Korea	047920
HLB SCIENCE Inc. Develops innovative therapeutics and diagnostics for infectious and neurodegenerative diseases.	South Korea	343090
H. Lundbeck A Develops and commercializes innovative therapeutics for brain diseases globally.	Denmark	HLUN
Hoth Therapeutics, Inc. Advancing therapeutics for metabolic, dermatologic, and inflammatory diseases.	United States of America	HOTH
Hugel, Inc. Global provider of medical aesthetic solutions like botulinum toxin and HA fillers.	South Korea	145020
Humacyte, Inc. Bioengineering off-the-shelf human tissues for vascular repair and regenerative medicine.	United States of America	HUMA